Tab Application Banner
  • Users Online: 593
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2009  |  Volume : 4  |  Issue : 3  |  Page : 112-118

Macrophage activation syndrome: I/II

1 Associate Professor (Pathology and Haematopathology), Department of Pathology, AFMC, Pune - 411040, India
2 Associate Professor (Medicine and Rheumatology), Department of Internal Medicine, AFMC, Pune - 411040, India

Correspondence Address:
J Kotwal
Associate Professor (Pathology and Haematopathology), Department of Pathology, AFMC, Pune - 411040
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Macrophage activation syndrome (MAS) is a potentially fatal systemic disorder which results from uncontrolled activation and proliferation of T cells and excessive activation of macrophages. It is a distinct clinicopathologic entity that occurs in different haemophagocytic syndromes (HSs). Primary haemophagocytic lymphohistiocytosis (HLH) is recognized to have an immunogenetic basis, but the secondary HS (also referred to as MAS) occurs in a number of autoimmune disorders including systemic onset juvenile idiopathic arthritis, SLE, adult onset Still's disease and other disorders. In first of the two part series, the aetiology, molecular pathogenesis and diagnostic features will be enunciated. The second part will deal with clinical features and management issues.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal